Codexis, Inc. (NASDAQ: CDXS) is a Healthcare company (Biotechnology) with a market capitalization of $117M. The Maz Rating grades it against the other companies in its sector.
Codexis, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.07, Codexis, Inc. trades at 1.3x sales and 2.2x book value. Over the last twelve months it generated about $90M of revenue and a net loss of $22M. It runs a gross margin of 83.9%, an operating margin of -14.4% and a net margin of -21.8%. It shows return on equity of -43.2%, return on invested capital of -10.2% and a free cash flow yield of -10.4%. On the balance sheet: a debt-to-equity ratio of 1.41 and a current ratio of 2.81. Over the past 52 weeks the share price ranged from $0.90 to $2.98, with a beta of 2.39.
Codexis, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 9 Buy and 5 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Codexis, Inc. (CDXS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 33.1% / 30% · (Cash+Inv) / Mkt Cap (36m) 60.4% / 30% · Interest income / Revenue 3.42% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 33.1% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 58.4% / 33% · Receivables / Mkt Cap (36m) 12.6% / 49% · Interest income / Revenue 3.42% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 33.1% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 58.4% / 33.33% · Receivables / Mkt Cap (24m) 12.6% / 33.33% · Interest income / Revenue 3.42% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 30.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 50.1% / 33.33% · Receivables / Avg Assets (4Q) 7.71% / 33.33% · Interest income / Revenue 3.42% / 5% | Fail |
| FTSE | Debt / Total Assets 28.6% / 33.33% · (Cash+ST Inv) / Total Assets 50.4% / 33.33% · (Cash+Recv) / Total Assets 61.2% / 33.33% · Interest income / Revenue 3.42% / 5% | Fail |
No. As of September 2026, Codexis, Inc. (CDXS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Codexis, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
About 3.42% of each dividend: Codexis, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.